|
|
 |
|
Viewing report
|
|
|
|
Trial TRAX - Multiple Sclerosis - Clinical Trial Monitoring Brief
Austin Research Analytics Group, Oct 2007, Pages: 23
The Multiple Sclerosis (MS) therapeutic market will experience a significant shift in power in the next five years. The current market leaders, Interferons and Copaxone, could lose their dominance to novel orally formulated and biologic treatments that offer superior convenience, efficacy, and quality of life for MS patients. The strong trend in the increased competitiveness of the oral class is also validated by the R&D efforts of the MS market leader, Biogen Idec (Avonex), who is investing heavily in 2 programs for oral drugs in phase 2 (CDP-323) and phase 3 (BG-12).
It is critical that stakeholders currently competing or considering entry into this hyper-competitive therapeutic market are well-informed with the latest intelligence on clinical trials of competitors of today and the future.
The Trial TRAX Clinical Intelligence Monitoring series provides detailed compilations and analysis of ongoing clinical studies within a specific therapeutic area or indication. Additionally, the Trial TRAX briefs contain synthesized background information on the profiled-disease including:
- Epidemiology
- Patient Segmentation
- Clinical endpoints
The Trial TRAX brief also contains analysis of the clinical landscape which comprises assessments including:
- % utilization of key clinical endpoints
- Number of ongoing trials (by phase of development)
- Key companies sponsoring clinical trials
Key data points from competitor clinical trials presented in the briefing include:
Study Drug
Mechanism of Action
Company-Sponsor
Phase of Development
Number of Patients
Study Design
Primary Endpoints
Study Start Date
The brief’s reference-guide format is designed to provide decision makers with easy access to key intelligence on competitive clinical development programs. The information contained within the report is updated on a quarterly basis to ensure accuracy, relevancy, and timeliness of the intelligence.
Clients utilize the Trial TRAX briefing reports to:
Monitor clinical development programs of competitors
Evaluate depth and breadth of competitive landscape
Identify potential patient recruitment challenges
Benchmark competitor clinical trial designs
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
